AI-Assisted PGx Report Drafting: Faster Sign-Out

Pharmacogenomics reporting has a deceptively repetitive surface and a genuinely high-stakes core. The genotype-to-phenotype-to-recommendation chain follows established logic, which makes it tempting to fully automate — and the consequences of a wrong drug-gene call make full automation unacceptable. The right model is AI-assisted drafting under tight, lab-validated control: let the system handle the structured assembly and plain-language drafting so sign-out is faster, while your qualified staff own the phenotype calls, the recommendations, and the signature. This article walks the PGx report flow, draws the line between where AI drafts and where the lab decides, and explains the audit trail that keeps it defensible.

The PGx report flow, step by step

Genotype

Testing produces genotypes for the relevant pharmacogenes, often reported as star (*) alleles for genes like CYP2D6 and CYP2C19. The assay and pipeline determine which alleles are detectable — and that scope is itself a reportable limitation.

Phenotype

Genotypes are translated into metabolizer phenotypes — poor, intermediate, normal, rapid, or ultrarapid — using established diplotype-to-phenotype logic. This translation follows defined rules, but it is a clinically meaningful determination, and the lab owns it. A system can present the standard mapping; qualified staff confirm the phenotype call.

Recommendation

The phenotype informs drug-gene guidance — for example, considerations around drugs metabolized by the affected enzyme. This is where established sources like CPIC guidelines and FDA drug labeling are relevant. The report conveys guidance the lab has validated and chosen to provide, framed appropriately and never as a directive that bypasses the prescriber.

Report

Finally, the structured findings, phenotype calls, and guidance are assembled into a readable report with the methods and limitations your lab requires. This assembly step is where AI drafting saves the most time. (See Labrynix specialty reports.)

Where AI drafts versus where the lab decides

Where AI legitimately drafts

• Plain-language summaries — turning structured results into a clear summary draft in your house style.
• Report formatting and assembly — populating tables, inserting the correct methods/limitations language for the assay, and producing a clean draft layout.
• Consistent boilerplate — the standardized explanatory text that should read the same way across every PGx report.
• Surfacing validated content — pulling the guidance text your lab has approved for a given drug-gene-phenotype combination, ready for reviewer confirmation.

Where the lab decides

• Phenotype determination — confirming the metabolizer phenotype from the genotype.
• Recommendation content — deciding what guidance to convey and how to frame it.
• Edge cases and ambiguity — complex diplotypes, conflicting evidence, or situations the standard rules don't cleanly cover.
• Sign-out — reviewing the full draft and signing. Nothing is released until a qualified person does this.

The line is consistent with everything a regulated lab already practices: AI assists; qualified lab staff validate, approve, and sign out. AI never makes the clinical decision.

CPIC, FDA, and PharmGKB — under the lab's validated rules

PGx content draws on well-known resources: CPIC guidelines for gene-drug pairs, FDA drug labeling with pharmacogenomic information, and PharmGKB knowledge. The crucial design principle is howthat content is used. These sources don't get pulled into a report blindly or in real time from the open internet. Instead, your lab curates and validates the content it intends to use — the genotype-phenotype mappings, the guidance text, the framing — and the AI system applies it under your configured rules. The system surfaces the right validated content for a given case; the lab decided in advance what that content says and keeps it current.

When guidelines or labeling change, your team updates the validated content, and that updated content flows into subsequent drafts. The lab controls the knowledge base; the AI accelerates its consistent application. (Background: what is pharmacogenomics testing.)

Built on foundation models, controlled by your rules

The drafting capability here comes from Labrynix's own AI system — agents, workflows, and lab-specific logic refined over years on real lab operations, built on top of best-in-class foundation models. It is not a from-scratch proprietary clinical model, and it is not an unconstrained chatbot. The foundation model provides fluent language generation; the Labrynix lab layer and your configuration provide the constraints, the validated content, and the guardrails that keep every draft inside your rules. That combination is what makes faster sign-out possible without losing control. (See Labrynix Intelligence and Labrynix PGx Reporting.)

The audit trail

In PGx, defensibility depends on being able to reconstruct exactly how a report came to be. A proper audit trail records:

• The inputs — the genotype data and case details the system worked from.
• The rule applied — which validated mapping or guidance content was used, and which version.
• The AI draft — what the system proposed.
• The human actions — every edit, confirmation, override, and the sign-out, attributed to the person who made it.

With this trail, a reviewer, auditor, or inspector can see that the system assisted within configured rules and that a qualified person made the determinations and signed out. The audit trail isn't paperwork for its own sake — it's what lets you move faster confidently, because you can always show your work. (See our security and compliance posture and the platform overview.)